Research discovery shows potential new approach to cancer treatment
The Garrett lab together with scientists at the Institute of Cancer Research (ICR) have published new work showing how the effectiveness of a new class of cancer drugs (known as CHK1 inhibitors) can be increased by also inhibiting the B-family of DNA polymerases within the tumour cells. This two-pronged approach can potentially kill cancers that do not response to a single-drug treatment.
The work also offers a new way of identifying those cancers most susceptible to CHK1 inhibitor treatment. The tumours with the lowest amounts of B-family DNA polymerases are least able to fight the killing effects of the drug and so respond best to treatment.
Read more about this exciting work at the University’s News Centre